GWPH studying CBD for schizophrenia & other hard-to-treat diseases

The pharmaceutical company that’s just made history by earning the FDA’s approval on a cannabis-plant-based drug (for epilepsy) is now racing ahead of the pack to do the same for schizophrenia and other hard-to treat diseases.

GW Pharmaceuticals’ Epidiolex® was approved following robust clinical trials that showed it as effective and well tolerated by children with rare forms of the disease.

The company also has “a deep pipeline” of additional cannabinoid product candidates, including compounds in development for epilepsy, autism, glioblastoma, and schizophrenia, it said in an August 2018 news release.

GW Pharmaceuticals has more that 20 patents for the medicinal use of its “proprietary oral solution of pure plant-derived cannabidiol.”

Copyright Notice © 2018. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to with appropriate and specific direction to the original content.


1 Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s